Pretreatment inflammatory indices predict Bevacizumab response in recurrent Glioma

作     者：Alicia Martínez-González Raquel Cabrera Marta Lloret Pedro C.Lara 

作者机构：Department de MatemáticasUniversidad de Castilla-La ManchaETSI IndustrialesAvdaCiudad Real 13071Spain. Oncología Radioterápica Hospital Universitario de Gran Canaria Dr NegrinBarranco de la Ballena s/nLas Palmas de Gran CanariaLas Palmas 35010Spain. Facultad de Ciencias de la SaludUniversidad de Las Palmas de Gran CanariaPaseo de Blas Cabrera Felipes/nLas Palmas de Gran CanariaLas Palmas 35016Spain. Fundación Canaria del Instituto Canario de Investigación del CáncerAvda de la Trinidad 61 Torre Agustín Arevalo 7 planta La LagunaSanta Cruz de Tenerife 38204Spain. San Roque University HospitalsDolores de la Rocha5Las Palmas de Gran CanariaLas Palmas 35001Spain. Fernando Pessoa Canarias UniversityDolores dela Rocha 14Las Palmas de Gran CanariaLas Palmas 35016Spain. 

出 版 物：《Cancer Drug Resistance》 (癌症耐药（英文）)

年 卷 期：2020年第3卷第3期

页      面：623-635页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：the Agencia Española de Medicamentos y Productos Sanitarios(ref:PLJ-BEV-2016-01) the Hospital Universitario de Gran Canaria Doctor Negrin committee(ref:170007) 

主　　题：Recurrent glioma bevacizumab predictive biomarker inflammatory indices lymphocytes 

摘      要：Aim:It remains unclear what the best therapeutic option for recurrent glioma patients after Stupp treatment ***(BVZ)is commonly administered in progression,but it appears that only some patients *** would be useful to find biomarkers that determine beforehand who these patients ***:The protocol included 31 high-risk progressing glioma patients after Stupp treatment who received BVZ 5-10 mg/kg every 14 days and temozolomide(3-19 cycles,150-200 mg five days each 28-day cycle)during a mean of eight cycles of BVZ or until tumor progression or unacceptable *** analyzed the clinical outcome values of inflammatory indices measured before BVZ ***:Lymphocyte level before BVZ administration was the best independent predictor of overall survival(HR=0.34;95%CI:0.145-0.81;P=0.015).The area under the receiver operating characteristic(ROC)curve was 0.823,with 1.645 being the optimal cut-off value,and 0.80 and 0.85 the sensitivity and specificity values,*** and non-responder survival curves were also significantly different,considering the first and second tertiles as cut-off *** number of BVZ cycles was not related to *** neutrophil platelet levels,platelet-to-lymphocyte ratio(PLR),and neutrophil-to-lymphocyte ratio(NLR)did not have independent predictive *** variables were not correlated with each ***,patients with high NLR and PLR simultaneously(double positive PLR-NLR)showed a worse clinical outcome than the rest(P=0.043).Conclusion:Pretreatment lymphocyte levels and double positive PLR-NLR could be used as non-invasive hematological prognostic markers for recurrent gliomas treated with bevacizumab.A close relationship emerged between inflammation and angiogenesis.